CN116077578A - Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof - Google Patents
Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof Download PDFInfo
- Publication number
- CN116077578A CN116077578A CN202211723254.7A CN202211723254A CN116077578A CN 116077578 A CN116077578 A CN 116077578A CN 202211723254 A CN202211723254 A CN 202211723254A CN 116077578 A CN116077578 A CN 116077578A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- respiratory syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 119
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 title claims description 35
- 238000002360 preparation method Methods 0.000 claims abstract description 45
- 239000002994 raw material Substances 0.000 claims description 28
- 238000002156 mixing Methods 0.000 claims description 22
- 244000144725 Amygdalus communis Species 0.000 claims description 20
- 235000011437 Amygdalus communis Nutrition 0.000 claims description 20
- 241000218671 Ephedra Species 0.000 claims description 20
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 20
- 235000020224 almond Nutrition 0.000 claims description 20
- 240000000691 Houttuynia cordata Species 0.000 claims description 19
- 235000013399 edible fruits Nutrition 0.000 claims description 19
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 19
- 235000011477 liquorice Nutrition 0.000 claims description 19
- 241000830535 Ligustrum lucidum Species 0.000 claims description 18
- 241001673966 Magnolia officinalis Species 0.000 claims description 18
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims description 17
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims description 17
- 235000008599 Poria cocos Nutrition 0.000 claims description 17
- 244000197580 Poria cocos Species 0.000 claims description 17
- 239000010440 gypsum Substances 0.000 claims description 17
- 229910052602 gypsum Inorganic materials 0.000 claims description 17
- 240000004980 Rheum officinale Species 0.000 claims description 16
- 235000008081 Rheum officinale Nutrition 0.000 claims description 16
- 241000045403 Astragalus propinquus Species 0.000 claims description 15
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 15
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 15
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 15
- 235000006533 astragalus Nutrition 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 235000013717 Houttuynia Nutrition 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 9
- 235000013719 Houttuynia cordata Nutrition 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 24
- 208000032625 disorder of ear Diseases 0.000 abstract description 22
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract description 2
- 229940088710 antibiotic agent Drugs 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 241000282887 Suidae Species 0.000 description 44
- 230000000052 comparative effect Effects 0.000 description 30
- 241000700605 Viruses Species 0.000 description 28
- 238000012360 testing method Methods 0.000 description 28
- 208000024891 symptom Diseases 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 206010011224 Cough Diseases 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000000463 material Substances 0.000 description 17
- 208000006673 asthma Diseases 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 238000009835 boiling Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 9
- 229960000329 ribavirin Drugs 0.000 description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 9
- 235000019786 weight gain Nutrition 0.000 description 9
- 230000036760 body temperature Effects 0.000 description 8
- 241000282898 Sus scrofa Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 102000003777 Interleukin-1 beta Human genes 0.000 description 6
- 108090000193 Interleukin-1 beta Proteins 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 238000005728 strengthening Methods 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000006992 Interferon-alpha Human genes 0.000 description 4
- 108010047761 Interferon-alpha Proteins 0.000 description 4
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000007779 soft material Substances 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229940126680 traditional chinese medicines Drugs 0.000 description 4
- 241000758794 Asarum Species 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 244000246386 Mentha pulegium Species 0.000 description 3
- 235000016257 Mentha pulegium Nutrition 0.000 description 3
- 235000004357 Mentha x piperita Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000001050 hortel pimenta Nutrition 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 240000004510 Agastache rugosa Species 0.000 description 2
- 241000605445 Anemarrhena asphodeloides Species 0.000 description 2
- 241000132012 Atractylodes Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000050051 Chelone glabra Species 0.000 description 2
- 208000003322 Coinfection Diseases 0.000 description 2
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 244000241463 Cullen corylifolium Species 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 240000002943 Elettaria cardamomum Species 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 208000009620 Orthomyxoviridae Infections Diseases 0.000 description 2
- 241001522129 Pinellia Species 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010040925 Skin striae Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 235000005300 cardamomo Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- ICVKYYINQHWDLM-KBEWXLTPSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4 Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 ICVKYYINQHWDLM-KBEWXLTPSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031636 Body Temperature Changes Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241001547127 Fritillaria cirrhosa Species 0.000 description 1
- 241000935235 Fritillaria meleagris Species 0.000 description 1
- 241000305491 Gastrodia elata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000112528 Ligusticum striatum Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 241000244269 Peucedanum Species 0.000 description 1
- 244000274050 Platycodon grandiflorum Species 0.000 description 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241001180876 Saposhnikovia Species 0.000 description 1
- 241000951473 Schizonepeta Species 0.000 description 1
- 208000004732 Systemic Vasculitis Diseases 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229960001717 tylosin tartrate Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/17—Gnetophyta, e.g. Ephedraceae (Mormon-tea family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Birds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a traditional Chinese medicine composition for treating pig blue ear disease and application thereof. The traditional Chinese medicine composition is prepared under the guidance of syndrome differentiation and treatment of middle veterinarian, and the combination of the medicines has remarkable effect on the treatment of damp-heat diseases such as blue ear disease and the like; the traditional Chinese medicine preparation is free of antibiotics, safe and effective, and free of drug resistance.
Description
Technical Field
The invention belongs to the technical field of veterinary traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof.
Background
Porcine reproductive and respiratory syndrome is also called porcine reproductive and respiratory syndrome, is a highly contagious disease caused by porcine reproductive and respiratory syndrome virus, and pigs of various varieties and different ages can be infected, but pregnant sows and piglets within 1 month of age are most susceptible. Pigs suffering from diseases and pigs with toxicity are important infectious sources of the diseases. The main transmission routes are contact infection, air transmission and semen transmission, and also can vertically transmit through placenta. The susceptible pigs can cause reproductive dysfunction, dyspnea, immunosuppression and the like after infection, and persistent infection is an important feature of epidemiology of the blue-ear disease, and the toxin expelling time can reach 251 days. The blue-ear disease is a first killer of a pig farm, not only is the damage to pigs caused by the disease and the economic loss caused by the disease, but also immunosuppression is caused after infection, other bacteria or viruses are easy to be secondarily infected to aggravate disease symptoms, and the death rate of piglets can reach 10-80%. The prognosis piglets will also develop poorly and even become stiff pigs, causing significant economic losses to the pig farmers.
At present, a plurality of strains and serotypes exist in China, different serotypes can appear in the same pig farm, and the cross protection effect of vaccines of different serotypes is weak, so that the vaccine immunization effect is not ideal; in addition, no special medicine is used for treating the porcine reproductive and respiratory syndrome, most measures aim at relieving acute symptoms, preventing secondary infection and reducing loss, such as a common antibiotic tilmicosin premix, tylosin tartrate and the like, less traditional Chinese medicines with obvious effects on the research and market of treating the porcine reproductive and respiratory syndrome are used, and the traditional Chinese medicine preparation with the effects of clearing heat, detoxicating, relieving cough, relieving asthma, eliminating dampness, promoting eruption and raising yang is very few when treating the porcine reproductive and respiratory syndrome. Therefore, the prevention and treatment of the blue-ear disease are well performed, the production performance of the positive pig farm is stabilized, great economic benefit can be brought to pig factories, and higher productivity can be brought to pig raising industry.
Patent CN104547870A claims a traditional Chinese medicine preparation for treating blue-ear disease and a preparation method and application thereof, wherein the traditional Chinese medicine preparation contains ephedra, almond, raw coix seed, cardamon seed, pinellia tuber, magnolia bark, ricepaper pith, talcum, wrinkled gianthyssop herb, liquorice and rhizoma atractylodis, has a certain control effect on clinical symptoms of blue-ear disease, but does not clearly indicate that the traditional Chinese medicine preparation has obvious improvement effect on the production performance of pigs suffering from blue-ear disease, and has few types of heat clearing and deficiency tonifying medicines, so that the traditional Chinese medicine preparation has no obvious effect on solving the symptoms of high fever of diseased pigs and the like.
Patent CN107998332A claims a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof, and contains saffron, fructus amomi, perilla, radix rehmanniae, gastrodia elata, ganoderan, mugwort leaf, glossy privet fruit, acanthopanax and dandelion. However, the recovery condition, cure rate and recurrence rate of the traditional Chinese medicine preparation on clinical symptoms of the blue-ear disease are not clearly indicated, and the traditional Chinese medicine preparation lacks phlegm-resolving cough-relieving asthma-relieving medicines, so that the treatment effect on cough-relieving pigs is not obvious, the clinically detected S/P value antibody level has certain hysteresis, and the S/P value directly measured after administration cannot be indicated to be the improvement of the antibody level after administration.
Patent CN106237050A claims a traditional Chinese medicine compound for effectively preventing and treating H1N1 and H3N2 swine influenza and porcine reproductive and respiratory syndrome and a preparation method thereof, wherein the traditional Chinese medicine compound contains ephedra, radix scutellariae, rhizoma anemarrhenae, fritillaria cirrhosa, almond, cordate houttuynia, cortex mori, rheum officinale and liquorice, and has obvious anti-reproductive and respiratory syndrome virus effect. However, the treatment condition of the traditional Chinese medicine compound for the pigs with the blue-ear disease is not clearly described, and the traditional Chinese medicine compound lacks the traditional Chinese medicines for eliminating dampness and tonifying, so that the traditional Chinese medicine compound cannot eliminate the damp evil in the bodies of the pigs with the blue-ear disease and has no obvious effect of improving the resistance of the pigs with the blue-ear disease.
Therefore, the development of a traditional Chinese medicine preparation which can simultaneously treat the blue-ear disease, can improve the symptoms such as fever, cough, asthma, skin erythema and the like caused by the blue-ear disease and can also improve the growth performance of sick pigs is urgently needed by the technicians in the field.
Disclosure of Invention
Through a great deal of research and practice, the invention provides a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof, and the composition can be prepared into a pharmaceutical preparation which is directly mixed in drinking water for use, and has the advantages of convenient administration, stable efficacy and high bioavailability. Animal experiments prove that the traditional Chinese medicine composition has the effects of promoting weight gain, improving clinical symptoms, reducing inflammatory response of porcine reproductive and respiratory syndrome, improving the defensive ability of organisms against viruses and the like for porcine reproductive and respiratory syndrome pigs.
In order to achieve the above object of the present invention, the following technical solutions are adopted:
the invention provides a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome, which is prepared from radix scutellariae, rhizoma anemarrhenae, rheum officinale, gypsum, houttuynia cordata, mint, rhizoma atractylodis, dried orange peel, poria cocos, magnolia officinalis, radix puerariae, glossy privet fruit, ephedra, almond, gynostemma pentaphylla, astragalus mongholicus, fructus psoraleae and liquorice.
The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 13-28 parts of radix scutellariae, 12-28 parts of rhizoma anemarrhenae, 1-13 parts of rheum officinale, 12-25 parts of gypsum, 6-22 parts of cordate houttuynia, 10-28 parts of mint, 2-16 parts of rhizoma atractylodis, 5-22 parts of dried orange peel, 5-20 parts of poria cocos, 4-22 parts of magnolia officinalis, 3-19 parts of radix puerariae, 1-14 parts of glossy privet fruit, 1-13 parts of ephedra, 5-20 parts of almond, 5-18 parts of gynostemma pentaphylla, 4-20 parts of astragalus mongholicus, 2-15 parts of fructus psoraleae and 1-11 parts of liquorice.
Preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 14-24 parts of radix scutellariae, 13-25 parts of rhizoma anemarrhenae, 2-10 parts of rheum officinale, 14-24 parts of gypsum, 7-20 parts of cordate houttuynia, 14-24 parts of mint, 3-15 parts of rhizoma atractylodis, 8-20 parts of dried orange peel, 6-18 parts of poria cocos, 6-18 parts of magnolia officinalis, 6-16 parts of radix puerariae, 3-10 parts of glossy privet fruit, 4-10 parts of ephedra, 6-15 parts of almond, 7-15 parts of gynostemma pentaphylla, 6-15 parts of astragalus mongholicus, 5-12 parts of fructus psoraleae and 1-7 parts of liquorice.
More preferably, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 16-20 parts of radix scutellariae, 16-20 parts of rhizoma anemarrhenae, 5-7 parts of rheum officinale, 16-20 parts of gypsum, 10-14 parts of cordate houttuynia, 16-20 parts of mint, 6-8 parts of rhizoma atractylodis, 10-14 parts of dried orange peel, 8-12 parts of poria cocos, 10-14 parts of magnolia officinalis, 8-12 parts of radix puerariae, 4-8 parts of glossy privet fruit, 6-8 parts of ephedra, 8-12 parts of almond, 8-12 parts of gynostemma pentaphylla, 10-14 parts of astragalus mongholicus, 6-8 parts of fructus psoraleae and 2-5 parts of liquorice.
Still more preferably, the weight portions of the raw materials in the traditional Chinese medicine composition are as follows: 18 parts of radix scutellariae, 18 parts of rhizoma anemarrhenae, 6 parts of rheum officinale, 18 parts of gypsum, 12 parts of houttuynia cordata, 18 parts of mint, 8 parts of rhizoma atractylodis, 12 parts of dried orange peel, 10 parts of poria cocos, 12 parts of magnolia officinalis, 10 parts of radix puerariae, 6 parts of glossy privet fruit, 8 parts of ephedra, 10 parts of almond, 10 parts of gynostemma pentaphylla, 12 parts of astragalus mongholicus, 8 parts of fructus psoraleae and 4 parts of liquorice.
The preparation method of the traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome comprises the steps of weighing raw material components according to selected parts by weight, mixing, and extracting according to a conventional extraction method or mixing according to a conventional method.
In a second aspect, the invention provides application of a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome in preparation of a pharmaceutical preparation for treating porcine reproductive and respiratory syndrome.
The pharmaceutical formulation may be, but is not limited to, a powder, a granule, an oral formulation, a soluble powder.
The dosage of the pharmaceutical preparation is as follows: 400g of the traditional Chinese medicine preparation is added into every 1000L of water, or 1000mL of the traditional Chinese medicine oral liquid is added into every 1000L of water.
In a third aspect, the invention provides an application of a traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome in preparing a feed additive for treating porcine reproductive and respiratory syndrome, wherein 400g of the traditional Chinese medicine composition is added into 1000L of water.
The traditional Chinese medicine composition is prepared by taking a basic theory of a middle veterinarian as a guide and conforming to the principle of dialectical treatment of the middle veterinarian. The porcine reproductive and respiratory syndrome belongs to the category of traditional veterinary 'pestilence' disease, and is caused by invasion of porcine body by heat toxin and damp evil, comprising the transmission of damp heat from upper, middle and lower triple energizer caused by the pathogenic factors of porcine reproductive and respiratory syndrome and damp heat environment: invasion of heat toxin and dampness begins at the upper jiao, and in the hands, damp-heat is accumulated in the interior, the striae and striae of the brown-and-Fu are closed and not communicated, and the pathogenic heat is affected, so that damp turbidity is accumulated in the interior, defensive qi is blocked, lung qi is not dispersed, and a water channel is not communicated; the upper part Jiao Wenbing is not treated and is transmitted to the middle energizer. The damp-heat evil further invaginates, stagnates the qi mechanism, stagnates the water-dampness, and the evil disturbs the spleen, and the viscera ascends and descends in heat Yu Wei; the lower Jiao Wenbing is caused by the failure of middle-jiao to warm disease, and damp-heat flowing downward stagnates the lower jiao, causing deficiency of both liver and kidney.
The traditional Chinese medicine composition has the advantages of having the effects of clearing away heat and toxic materials, reducing fever, removing dampness, purging pathogenic fire, removing toxic substances, having the effects of bitter and sweet taste of rhizoma anemarrhenae, having the effects of clearing away heat, promoting the production of body fluid, moistening dryness, clearing lung-heat, cooling stomach heat in middle-jiao and purging kidney fire in lower-jiao, and being used as a monarch drug; rhubarb, radix et rhizoma Rhei, bitter in taste, cold in nature, purgation and accumulation in the body, heat-clearing and fire-purging, blood-cooling and toxin-removing, stasis-removing and menstruation-promoting, gypsum, pungent and sweet in nature, slightly cold in nature, heat-clearing and fire-purging, restlessness-relieving and thirst-quenching, heartleaf houttuynia herb, slightly bitter, slightly cold in nature, heat-clearing and toxin-removing, carbuncle-eliminating and pus-expelling, peppermint, cool, heat-clearing and toxin-removing, carbuncle-eliminating and pus-expelling, diuresis-inducing and stranguria-relieving are combined, and are used as ministerial drugs together to enhance the efficacy of the monarch drug in heat-clearing and toxin-removing; the Chinese atractylodes is pungent and bitter, warm, dry dampness and invigorate spleen, expel wind and remove cold, bitter and pungent dried orange peel, warm, regulate qi and invigorate spleen, dry dampness and resolve phlegm, poria cocos is sweet and light, flat, diuresis and remove dampness, invigorate spleen, calm heart, magnolia officinalis and remove heat, warm, dry dampness and remove phlegm, lower qi and remove fullness, kudzu vine root is sweet and pungent, cool, myo-thermal relieving, eruption promoting, salivation promoting and thirst quenching, yang-ascending and antidiarrheal, ephedra is pungent, slightly bitter, warm, sweat and exterior relieving, lung-dispersing and asthma relieving, diuresis and detumescence promoting, almond bitter, slightly warm, qi-descending and cough relieving and asthma relieving, intestine relaxing bowel, glossy privet fruit sweet and bitter, cool, liver and kidney, tendons and bones strengthening, gynostemma pentaphylla bitter, cold, anti-inflammatory and detoxication relieving cough and eliminating phlegm, astragalus mongholicus, slightly warm, strengthening spleen and tonifying middle-jiao, yang-ascending and qi and resolving, and strengthening body resistance, malaytea, and pungent, warming spleen and antidiarrheal are all adjuvant drugs; licorice is sweet, calm, invigorate spleen and replenish qi, clear away heat and toxic material, dispel phlegm and relieve cough, relieve urgency and stop pain, and harmonize various drugs, which are guiding drugs. The medicines are combined to play the roles of clearing heat and detoxicating, relieving cough and promoting eruption, strengthening spleen and clearing lung-heat, drying dampness and raising yang.
The formula principle of the invention is as follows: clearing heat and detoxicating, relieving cough and promoting eruption, strengthening spleen and clearing lung-heat, eliminating dampness and raising yang, clearing heat, purging damp-heat in upper, middle and lower three-jiaos, and treating both lung, spleen and kidney.
The beneficial effects of the invention are as follows:
1. the traditional Chinese medicine composition is prepared from 18 traditional Chinese medicines, has no antibiotics and no drug resistance, is safe and reliable, has the effects of clearing heat and detoxicating, relieving cough and promoting eruption, strengthening spleen and clearing lung-heat, drying dampness and raising yang, and achieves the effect of effectively treating the pigs with the blue-ear diseases by regulating the organism and inhibiting the blue-ear viruses.
2. The traditional Chinese medicine composition provided by the invention has the advantages that the preparation process is simple, the administration mode is simple and convenient, the obtained medicinal preparation can be mixed for use, can be used by drinking water, and has high bioavailability.
3. The traditional Chinese medicine composition can also relieve slow growth of pigs caused by blue-ear disease, and has the effect of improving the growth performance of sick pigs.
Detailed Description
Embodiments of the present invention will now be described in detail with reference to the following examples, which are only illustrative of the present invention and should not be construed as limiting the scope of the invention.
Example 1
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
24 parts of radix scutellariae, 25 parts of rhizoma anemarrhenae, 10 parts of rheum officinale, 24 parts of gypsum, 20 parts of houttuynia cordata, 24 parts of mint, 15 parts of rhizoma atractylodis, 20 parts of dried orange peel, 18 parts of poria cocos, 18 parts of magnolia officinalis, 16 parts of radix puerariae, 10 parts of glossy privet fruit, 10 parts of ephedra, 15 parts of almond, 15 parts of gynostemma pentaphylla, 15 parts of astragalus membranaceus, 12 parts of fructus psoraleae and 7 parts of liquorice.
The preparation process comprises the following steps:
(1) Weighing the required raw materials according to the weight, mixing the raw materials, adding the mixture into an extraction tank, adding 10 times of water into the raw materials, soaking for 45 minutes, heating and boiling, extracting for 2 hours, filtering, and collecting filtrate I for later use;
(2) Adding 10 times of water into the residue, boiling, extracting for 1.5 hr, filtering, and mixing with filtrate I to obtain extractive solution;
(3) Concentrating the extract to 1g crude drug per mL;
(4) Spray drying the concentrated solution to obtain dry powder of the traditional Chinese medicine extract;
(5) Adding proper amounts of auxiliary materials sucrose and dextrin into the dry powder of the traditional Chinese medicine extract, uniformly mixing to ensure that each g contains 2.5g of crude medicine, then spraying proper amount of 75% ethanol to prepare a soft material which is held, agglomerated and pinched to be dispersed, granulating in a swinging granulator, and drying, granulating and packaging to obtain the traditional Chinese medicine preparation, wherein the dosage form is granules.
Example 2
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
22 parts of radix scutellariae, 22 parts of rhizoma anemarrhenae, 8 parts of rheum officinale, 22 parts of gypsum, 18 parts of houttuynia cordata, 22 parts of mint, 14 parts of rhizoma atractylodis, 18 parts of dried orange peel, 16 parts of poria cocos, 16 parts of magnolia officinalis, 14 parts of radix puerariae, 10 parts of glossy privet fruit, 10 parts of ephedra, 14 parts of almond, 14 parts of gynostemma pentaphylla, 15 parts of astragalus membranaceus, 10 parts of fructus psoraleae and 6 parts of liquorice.
The preparation process comprises the following steps: the preparation method comprises the steps of respectively weighing the required raw materials according to weight, respectively crushing the raw materials, sieving with a 80-mesh sieve, and uniformly mixing to obtain the traditional Chinese medicine powder.
Example 3
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
18 parts of radix scutellariae, 18 parts of rhizoma anemarrhenae, 6 parts of rheum officinale, 18 parts of gypsum, 12 parts of houttuynia cordata, 18 parts of mint, 8 parts of rhizoma atractylodis, 12 parts of dried orange peel, 10 parts of poria cocos, 12 parts of magnolia officinalis, 10 parts of radix puerariae, 6 parts of glossy privet fruit, 8 parts of ephedra, 10 parts of almond, 10 parts of gynostemma pentaphylla, 12 parts of astragalus mongholicus, 8 parts of fructus psoraleae and 4 parts of liquorice.
The preparation process comprises the following steps:
(1) Weighing the required raw materials according to the weight, mixing the raw materials, adding the mixture into an extraction tank, adding 10 times of water into the raw materials, soaking for 45 minutes, heating and boiling, extracting for 2 hours, filtering, and collecting filtrate I for later use;
(2) Adding 10 times of water into the residue, boiling, extracting for 2 hr, filtering, and mixing with filtrate I to obtain extractive solution;
(3) Concentrating the extract to 1g crude drug per mL;
(4) Spray drying the concentrated solution to obtain dry powder of the traditional Chinese medicine extract;
(5) Adding proper amounts of auxiliary materials sucrose and dextrin into the dry powder of the traditional Chinese medicine extract, uniformly mixing to ensure that each g contains 2.5g of crude medicine, then spraying proper amount of 75% ethanol to prepare a soft material which is held, agglomerated and pinched to be dispersed, granulating in a swinging granulator, and drying, granulating and packaging to obtain the traditional Chinese medicine preparation, wherein the dosage form is granules.
Example 4
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
14 parts of radix scutellariae, 13 parts of rhizoma anemarrhenae, 2 parts of rheum officinale, 14 parts of gypsum, 7 parts of houttuynia cordata, 14 parts of mint, 3 parts of rhizoma atractylodis, 8 parts of dried orange peel, 6 parts of poria cocos, 6 parts of magnolia officinalis, 6 parts of radix puerariae, 3 parts of glossy privet fruit, 4 parts of ephedra, 6 parts of almond, 7 parts of gynostemma pentaphylla, 6 parts of astragalus mongholicus, 5 parts of fructus psoraleae and 1 part of liquorice.
The preparation process comprises the following steps:
(1) Weighing the required raw materials according to the weight, mixing the raw materials, adding the mixture into an extraction tank, adding 10 times of water into the raw materials, soaking for 40 minutes, heating and boiling, extracting for 2.5 hours, filtering, and collecting filtrate I for later use;
(2) Adding 10 times of water into the residue, boiling, extracting for 1.5 hr, filtering, and mixing with filtrate I to obtain extractive solution;
(3) Concentrating the extract to 1g crude drug per mL;
(4) Spray drying the concentrated solution to obtain dry powder of the traditional Chinese medicine extract;
(5) Adding a proper amount of sucrose powder (80 meshes) into the dry powder of the traditional Chinese medicine extract, and uniformly mixing to ensure that each g contains 2.5g of crude medicine, and packaging to obtain the traditional Chinese medicine preparation provided by the invention, wherein the dosage form is soluble powder.
Example 5
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
16 parts of radix scutellariae, 16 parts of rhizoma anemarrhenae, 5 parts of rheum officinale, 16 parts of gypsum, 10 parts of cordate houttuynia, 16 parts of mint, 6 parts of rhizoma atractylodis, 10 parts of dried orange peel, 8 parts of poria cocos, 10 parts of magnolia officinalis, 8 parts of radix puerariae, 4 parts of glossy privet fruit, 6 parts of ephedra, 8 parts of almond, 8 parts of gynostemma pentaphylla, 10 parts of astragalus mongholicus, 6 parts of fructus psoraleae and 2 parts of liquorice.
The preparation process comprises the following steps:
(1) Weighing the required raw materials according to the weight, mixing the raw materials, adding the mixture into an extraction tank, adding 10 times of water into the raw materials, soaking for 45 minutes, heating and boiling, extracting for 1.5 hours, filtering, and collecting filtrate I for later use;
(2) Adding 10 times of water into the residue, boiling, extracting for 1.5 hr, filtering, and mixing with filtrate I to obtain extractive solution;
(3) Concentrating the extract to 1g crude drug per mL;
(4) Spray drying the concentrated solution to obtain dry powder of the traditional Chinese medicine extract;
(5) Adding proper amounts of auxiliary materials sucrose and dextrin into the dry powder of the traditional Chinese medicine extract, uniformly mixing to ensure that each g contains 2.5g of crude medicine, then adding water to prepare a soft material, placing the soft material into a swing granulator to prepare granules, and drying, granulating and packaging to obtain the traditional Chinese medicine preparation of the invention, wherein the dosage form is granules.
Example 6
The traditional Chinese medicine preparation comprises the following raw medicinal materials in parts by weight:
26 parts of baical skullcap root, 26 parts of common anemarrhena rhizome, 12 parts of rhubarb, 25 parts of gypsum, 22 parts of heartleaf houttuynia herb, 26 parts of peppermint, 16 parts of swordlike atractylodes rhizome, 22 parts of tangerine peel, 20 parts of Indian buead, 20 parts of officinal magnolia bark, 18 parts of kudzuvine root, 12 parts of glossy privet fruit, 12 parts of Chinese ephedra, 18 parts of apricot kernel, 16 parts of fiveleaf gynostemma herb, 18 parts of membranous milkvetch root, 14 parts of malaytea scurfpea fruit and 10 parts of liquoric root.
The preparation process comprises the following steps:
(1) Respectively weighing the required raw materials according to the weight, mixing the raw materials, adding the mixture into an extraction tank, adding 10 times of water into the raw materials, soaking for 30 minutes, heating and boiling, extracting for 2.5 hours, filtering, and collecting filtrate I for later use;
(2) Adding 10 times of water into the residue, boiling, extracting for 2.5 hr, filtering, and mixing with filtrate I to obtain extractive solution;
(3) Concentrating the extractive solution to 1g crude drug per mL, adding 0.3% potassium sorbate, and dissolving uniformly to obtain the final product.
Comparative example 1
A traditional Chinese medicine preparation for treating blue-ear disease comprises the following components in parts by weight: 200g of ephedra, 250g of almond, 350g of raw coix seed, 200g of cardamon seed, 200g of pinellia tuber, 300g of magnolia bark, 50g of ricepaper pith, 100g of talcum, 100g of wrinkled gianthyssop, 50g of liquorice and 200g of rhizoma atractylodis.
The preparation process comprises the following steps: mixing the above materials, mixing with water 5 times of the total weight of the materials, decocting at 60-100deg.C for 30min, filtering, decocting the residue with water of equal amount once, mixing the filtrates, and concentrating to 1g/mL.
The above formulation process is referred to in example 2 of patent CN104547870 a.
Comparative example 2
A traditional Chinese medicine compound preparation for treating porcine reproductive and respiratory syndrome comprises the following raw materials in parts by weight: 6 parts of schizonepeta, 10 parts of divaricate saposhnikovia root, 6 parts of bupleurum, 6 parts of peucedanum root, 6 parts of notopterygium root, 6 parts of radix angelicae pubescentis, 6 parts of ginseng rootlet, 6 parts of burdock, 6 parts of fructus aurantii, 6 parts of poria cocos, 6 parts of platycodon grandiflorum, 6 parts of ligusticum wallichii, 6 parts of liquorice, 6 parts of peppermint, 6 parts of radix scutellariae and 6 parts of radix trichosanthis.
The above formulation and its process are as described in example 1 of CN104474083 a.
Comparative example 3
A Chinese herbal compound for effectively preventing and treating H1N1 and H3N2 swine influenza and porcine reproductive and respiratory syndrome comprises the following components in parts by weight: 200g of ephedra herb, 200g of baical skullcap root, 90g of common anemarrhena rhizome, 90g of unibract fritillary bulb, 90g of almond, 90g of heartleaf houttuynia herb, 90g of white mulberry root-bark, 90g of rhubarb and 60g of liquoric root.
The preparation process comprises the following steps: weighing and combining traditional Chinese medicinal materials in a formula, crushing to 20 meshes, adding 2000g of water into the mixture, soaking the mixture for 1h, heating the mixture to boiling, decocting the mixture for 30min, filtering the mixture, adding equal amount of water into dregs, heating the mixture to boiling, filtering the mixture, combining the filtrate with the filtrate I to obtain an extracting solution, carrying out suction filtration and concentration on the extracting solution under normal pressure and vacuum conditions, fixing the volume to 1000mL to obtain a concentrated solution, and sterilizing and preserving the concentrated solution.
The above formulation process is described in the specification of patent CN106237050 a.
Test example 1 in vitro antiviral Effect test
1. Purpose of test
Verification of the anti-blue-ear virus effect of the product
2. Test materials
Test cells and viruses: monkey kidney cells, highly pathogenic porcine reproductive and respiratory syndrome virus.
Test drug: samples for this experiment were provided by the veterinary drug development center of Tianjin Reep Biotechnology, inc., pharmaceutical research and development center, test group was inventive example 1 (1000 g/bag, lot number: 20220301), example 3 (1000 g/bag, lot number: 20220303), example 4 (1000 g/bag, lot number: 20220304), comparative example 1 (1000 mL/bottle, lot number: 20220307), comparative example 3 (1000 mL/bottle, lot number: 20220309); ribavirin is manufactured by a commercial manufacturer (50 mg/bag, lot number: 200312).
Preparation of test samples: examples 1, 3 and 4 were dissolved in DMEM basal medium to a concentration of 1g crude drug/mL and filtered through a 0.22 μm filter membrane for further use. The products of comparative example 1 and comparative example 3 were centrifuged at 3000rpm for 10min, and the supernatant was collected and filtered with a 0.22 μm filter membrane for use. Ribavirin is dissolved in DMEM basal medium to make the concentration of ribavirin 10mg/mL, and the ribavirin is filtered by a 0.22 mu m filter membrane for later use.
3. Test method
3.1 inhibition of virus by drug: diluting the positive drug ribavirin (5 mg crude drug/mL in the examples 1, 3 and 4 and the concentrations of ribavirin in the comparative examples 1 and 3 and the concentrations of ribavirin Lin Nongdu are 0.1 mg/mL) in the examples 1, 3 and 4 by using a culture medium, firstly inoculating virus liquid into a 96-well cell culture plate full of monolayer cells, incubating for 2 hours at 37 ℃, and absorbing and discarding the virus liquid; the medicinal liquid was added to each well at a concentration of 100. Mu.L/well, 5 wells were repeated, and the culture was continued at 37℃for 4 hours, followed by discarding the above-mentioned medicinal liquid. mu.L of cell-retaining solution was added to each well, and the culture was continued for 5 days, and the OD value of each well was measured by the CCK8 method.
3.2 blocking effect of drug on virus: after cells were grown to a monolayer in 96-well plates, each of the drug administration was added with a drug solution, 100. Mu.L/well, 5 wells were repeated at each concentration, the drug solution was cultured at 37℃for 4 hours, the drug solution was added, 100. Mu.L/well, the drug solution was cultured at 37℃for 2 hours, 100. Mu.L of a cell maintenance solution was added, and the culture was continued for 5 days, and OD values of each well was measured by CCK8 method.
3.3 direct inactivation of virus by drug: after cells were grown to a monolayer in 96-well plates, each of the drug administration was added with a drug solution at 100. Mu.L/well, and at the same time with a drug solution at 100. Mu.L/well, 5 wells were repeated at each concentration, and after 4 hours of culture at 37℃the culture solution was discarded, 100. Mu.L of cell maintenance solution was added to each well, and the culture was continued for 5 days, and OD values of each well was measured by CCK8 method.
A blank (blank containing cells, medium) and a virus model (virus model containing cells, medium, blue ear virus) were set simultaneously.
3.4, calculating according to the formula: drug protection against virus-infected cells = (drug treatment OD value-virus model OD value)/(placebo OD value-virus model OD value) ×100%.
4. Test results
As shown in table 1, ribavirin as a positive drug has an effective protective effect on blue ear virus infected cells with a protective rate of more than 50%; example 3 has a protection rate of over 20% for the blue-ear virus infected cells, and is effective in protecting the infected cells.
TABLE 1 protection ratio of different drugs against cells (%)
| Group of | Inhibition effect | Blocking effect | Direct inactivation |
| Example 1 (5 mg/mL) | 15.4 | 26.5 | 19.8 |
| Example 3 (5 mg/mL)) | 29.0 | 30.3 | 43.0 |
| Example 4 (5 mg/mL) | 20.3 | 19.5 | 23.9 |
| Ribavirin (0.1 mg/mL) | 51.6 | 62.1 | 58.7 |
| Comparative example 1 (5 mg/mL) | 15.7 | 24.5 | 22.0 |
| Comparative example 3 (5 mg/mL) | 28.3 | 25.9 | 20.4 |
Remarks: drug protection rate for virus-infected cells= (drug treatment group OD value-virus model group OD value)/(blank control group OD value-virus model group OD value) ×100%; cell protection rate: 10% -20% of low protection rate, 20% -30% of higher protection rate, and more than 30% of high protection rate.
5. Conclusion(s)
The test results show that the traditional Chinese medicine preparation has obvious anti-blue-ear virus effect; the virus can be prevented from replicating in cells by blocking virus adsorption cells, so that the aim of resisting viruses is fulfilled, and the virus killing effect is extremely strong. In the aspects of inhibiting, blocking and directly inactivating viruses of the medicaments, the protection rate of the product of the embodiment 3 on infected cells can reach 29%,30.3% and 43%, and the effect is better than other embodiments and comparative examples.
Test example 2 test of Effect on growth Properties and clinical symptoms of blue-ear pigs
1. Test materials
Test animals: white pigs, male and female pigs are half-divided; day-age: healthy piglets at 35 days of age; weight of: 8+ -0.8 kg.
Test drug: example 2 (1000 g/bag, lot number: 20220302), example 3 (1000 g/bag, lot number: 20220303), comparative example 1 (1000 mL/bottle, lot number: 20220307), comparative example 2 (1000 g/bag, lot number: 20220308).
Virus: blue ear virus (hypervirulent strain).
2. Test method
2.1 grouping and processing: blue-ear double-negative healthy piglets 36 are selected, adaptively raised for one week and randomly divided into 6 groups of 6 piglets each. Wherein, the nasal drops of physiological saline for 6 pigs in a blank group are 2.5mL (normal daily ration is fed); the other groups were each given a proper amount of blue ear virus diluent by nasal drip, and a model was established (the virus titer used by the patients who had been tested to be blue ear positive by PCR after 7d of challenge and had developed clinical cough and asthma was the nasal drop dose), and then the model groups (feeding normal daily ration), example 2 group (0.1% mixed feed treatment, continuous feed 14 d), example 3 group (0.025% drinking water treatment, continuous feed 14 d), comparative example 1 group (0.1% drinking water treatment, continuous feed 14 d), comparative example 2 group (0.3% mixed feed treatment, continuous feed 14 d), and pigs of each group were individually fed into different negative pressure chambers.
2.2 daily recordings are made to observe clinical symptoms.
2.3 record body weights of groups of pigs 7d, 14d with challenge.
2.4 stopping administration for 14d, collecting blood, and detecting the levels of IL-1β, IFN- α and TNF- α in serum.
2.5 stopping taking medicine for 14d, and observing pathological section.
3. Test results
3.1 clinical observations
The model group has obvious clinical symptoms such as reduced feed intake, cough, asthma and the like in the whole test period; administering 7d, wherein most pigs in the group of the example 3 have normal diet, and the cough and asthma symptoms are relieved; administration for 14d, all pigs in example 2, 3 had no cough and asthma symptoms; administration for 14d, 50% of the pigs in the comparative example 1 group had reduced cough and asthma symptoms, and 20% of the pigs in the comparative example 2 group had reduced cough and asthma symptoms.
3.2 weight gain conditions
After 7d of challenge, the weight gain rate of pigs in each challenge group is reduced compared with that of a blank group, which indicates that 7-14d has a larger influence on organisms after the challenge of the blue-ear virus, and the weight gain rate of the group of the embodiment 2 and the group of the embodiment 3 is superior to that of the group of the embodiment 1 and the group of the embodiment 2 when 7d and 14d are subjected to trial administration. Wherein the weight gain effect of the group of the example 3 is most remarkable, the weight gain rate of the drug withdrawal 14d is higher than that of the model group by 33.4 percent, the weight gain rate of the drug withdrawal 14d is higher than that of the group of the comparative example 1 by 21.17 percent, and the weight gain rate of the drug withdrawal 14d is higher than that of the group of the comparative example 2 by 27.44 percent.
Table 2 weight gain rate of pigs in each test group
3.3 inflammatory factor level results
As can be seen from table 3, the levels of IL-1 β and TNF- α in the serum of the model group blue-ear disease pigs were extremely significantly increased and the levels of IFN- α were extremely significantly decreased (P < 0.01) compared to the blank group; compared with the model group, the IL-1 beta level in the serum of the blue-ear disease pigs of the groups 2 and 3 and the comparison example 1 is extremely obviously reduced (P < 0.01), the IFN-alpha level in the serum of the blue-ear disease pigs of the groups 2 and 3 is obviously increased (P <0.01 or P < 0.05), and the TNF-alpha level in the serum of the blue-ear disease pigs of the groups 2 and 3 is extremely obviously reduced (P < 0.01).
TABLE 3 inflammatory factor levels for groups
| Group of | IL-1β(pg/mL) | IFN-α(pg/mL) | TNF-α(pg/mL) |
| Blank group | 57.85±6.29 | 33.87±2.75 | 154.48±14.62 |
| Model group | 127.20±11.85 ** | 26.21±1.98 ** | 221.08±19.81 ** |
| Example 2 group | 79.01±8.02 ## | 30.10±2.84 # | 166.47±15.12 ## |
| Example 3 group | 65.69±5.24 ## | 34.05±2.69 ## | 159.26±14.17 ## |
| Comparative example 1 group | 77.36±7.12 ## | 29.67±2.41 * | 182.26±19.35 |
| Comparative example 2 group | 101.76±9.18 ** | 28.69±1.83 * | 201.47±13.20 ** |
Remarks: compared to the blank, the difference was very significant (P < 0.01) and the difference was significant (P < 0.05). Compared to the model group, # represents the most significant difference (P < 0.01) and # represents the significant difference (P < 0.05).
3.4 pathological section inspection and observation
The blank group and the groups of the pigs in the examples 2 and 3 have no obvious pathological changes of lung, spleen, liver, kidney and lymph node; pleural effusion, inguinal lymph node swelling and congestion are severe, lung congestion, sarcoidosis, and spleen edge bleeding are severe in pigs of the model group; inguinal lymph node swelling and slight congestion, lung sarcoidosis in pigs of comparative example 1; comparative example 2 pigs had a small amount of pleural effusion, inguinal lymph node swelling and congestion, and lung congestion.
4. Conclusion(s)
The inflammatory factor IL-1 beta plays an important role in innate immunity, and it has been reported that HP-PRRSV strains can activate NLRP3 inflammatory corpuscles, induce the production of IL-1 beta, and the over-expression of IL-1 beta can cause lung lesions of organisms, damage immune organs, and cause systemic vasculitis and secondary infection. In the organism infected with PRRSV, IFN-alpha has the functions of resisting virus proliferation, regulating immunity and the like, so IL-1 beta and IFN-alpha cytokines in the immunity of the PRRSV are selected for detection, and the test results show that the traditional Chinese medicine preparation in the embodiment 2 and the embodiment 3 of the invention has the functions of reducing inflammatory reaction of porcine reproductive and respiratory syndrome, improving the defending ability of the organism to viruses, remarkably promoting the weight increase of porcine reproductive and respiratory syndrome and reducing pathological changes of tissues and organs, wherein the traditional Chinese medicine preparation in the embodiment 3 has the best effect.
Test example 3 clinical Effect test
1. Test materials
Test animals: the trunk of a pig farm in Shandong province is 32, the body temperature is raised to about 40-41 ℃, the pigs cough, sneeze and asthma, part of pigs are dyspnea, the body surface is red, the abdomen is red, and the feces are dry or thin, and the blue-ear disease is diagnosed.
Test drug: the samples for this experiment were provided by the veterinary drug research and development center of Tianjin Reep Biotechnology Co., ltd., example 3 (1000 g/bag, lot number: 20220303), and comparative example 1 (1000 mL/bottle, lot number: 20220307).
2. Test method
2.1 administration treatment: the sick pigs were randomly divided into 2 groups, and the traditional Chinese medicine preparation provided in the example 3 of the invention was used for 0.025% drinking water administration treatment, and the product of the comparative example 1 was used for 0.1% drinking water administration treatment, and the administration was continued for 2 weeks.
2.2 daily observations and recordings of clinical symptoms and clinical symptom scores were made.
2.3 body temperature is detected and recorded.
3. Test results
3.1 clinical symptom scoring
Scoring was performed according to clinical symptoms, and scoring criteria were set as follows:
table 4 scoring criteria table
The clinical symptom scoring results of the two test groups show that the symptom scoring values before treatment are higher; for 7d, the clinical symptom scores of the two groups were in a decreasing trend, and the clinical symptom score of the example 3 group was lower than that of the comparative example 1 group; the group of example 3 had no significant clinical symptoms with administration of 14d and withdrawal of 14 d. Demonstrating that example 3 of the present invention significantly improved the clinical symptoms of blue-ear patient pigs compared to comparative example 1.
Table 5 average (score) of clinical symptoms score for two groups of pigs
| Group of | Pre-dose scoring | Dosing 7d score | Administration 14d score | Withdrawal 14d score |
| Example 3 group | 5±1.49 | 1.8±1.14 | 0 | 0 |
| Comparative example 1 group | 4.8±1.52 | 4.2±0.75 | 1.2±0.64 | 0.6±0.89 |
3.2 results of body temperature changes
The body temperature detection results of the two test groups show that the body temperature of the administration precursor is in a middle burning state; administration for 7d, example 3 group body temperature had a decreasing trend; the administration of 14d and the stopping of 14d, example 3 has normal body temperature, and compared with comparative example 1, the invention can quickly and effectively regulate the body temperature to be normal, which shows that the invention of example 3 can obviously improve the hyperthermia symptoms of pigs with blue ear patients.
Table 6 average body temperature (. Degree.C.) of two pigs
| Group of | Before administration of the drug | Administration for 7d | Administration 14d | Stopping the medicine 14d |
| Example 3 group | 40.6±0.33 | 40.2±0.29 | 39.2±0.27 | 39.2±0.24 |
| Comparative example 1 group | 40.7±0.34 | 40.7±0.39 | 40.3±0.31 | 39.5±0.19 |
4. Conclusion(s)
From the above test results, it can be seen that the clinical symptoms of cough and asthma, runny nose, diarrhea, high fever and the like of the blue-ear patients can be significantly improved in the embodiment 3 of the invention.
While specific embodiments of the invention have been described above, it will be appreciated by those skilled in the art that the specific embodiments described are illustrative only and not intended to limit the scope of the invention, and that equivalents and modifications, in accordance with the spirit of the invention, will be within the scope of the invention as defined by the appended claims.
Claims (9)
1. A traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome is characterized by comprising radix scutellariae, rhizoma anemarrhenae, rheum officinale, gypsum, cordate houttuynia, mint, rhizoma atractylodis, dried orange peel, poria cocos, mangnolia officinalis, radix puerariae, glossy privet fruit, ephedra, almond, gynostemma pentaphylla, radix astragali, fructus psoraleae and liquorice.
2. The traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 13-28 parts of radix scutellariae, 12-28 parts of rhizoma anemarrhenae, 1-13 parts of rheum officinale, 12-25 parts of gypsum, 6-22 parts of cordate houttuynia, 10-28 parts of mint, 2-16 parts of rhizoma atractylodis, 5-22 parts of dried orange peel, 5-20 parts of poria cocos, 4-22 parts of magnolia officinalis, 3-19 parts of radix puerariae, 1-14 parts of glossy privet fruit, 1-13 parts of ephedra, 5-20 parts of almond, 5-18 parts of gynostemma pentaphylla, 4-20 parts of astragalus mongholicus, 2-15 parts of fructus psoraleae and 1-11 parts of liquorice.
3. The traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome according to claim 2, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 14-24 parts of radix scutellariae, 13-25 parts of rhizoma anemarrhenae, 2-10 parts of rheum officinale, 14-24 parts of gypsum, 7-20 parts of cordate houttuynia, 14-24 parts of mint, 3-15 parts of rhizoma atractylodis, 8-20 parts of dried orange peel, 6-18 parts of poria cocos, 6-18 parts of magnolia officinalis, 6-16 parts of radix puerariae, 3-10 parts of glossy privet fruit, 4-10 parts of ephedra, 6-15 parts of almond, 7-15 parts of gynostemma pentaphylla, 6-15 parts of astragalus mongholicus, 5-12 parts of fructus psoraleae and 1-7 parts of liquorice.
4. The traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome according to claim 3, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 16-20 parts of radix scutellariae, 16-20 parts of rhizoma anemarrhenae, 5-7 parts of rheum officinale, 16-20 parts of gypsum, 10-14 parts of cordate houttuynia, 16-20 parts of mint, 6-8 parts of rhizoma atractylodis, 10-14 parts of dried orange peel, 8-12 parts of poria cocos, 10-14 parts of magnolia officinalis, 8-12 parts of radix puerariae, 4-8 parts of glossy privet fruit, 6-8 parts of ephedra, 8-12 parts of almond, 8-12 parts of gynostemma pentaphylla, 10-14 parts of astragalus mongholicus, 6-8 parts of fructus psoraleae and 2-5 parts of liquorice.
5. The traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome according to claim 4, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 18 parts of radix scutellariae, 18 parts of rhizoma anemarrhenae, 6 parts of rheum officinale, 18 parts of gypsum, 12 parts of houttuynia cordata, 18 parts of mint, 8 parts of rhizoma atractylodis, 12 parts of dried orange peel, 10 parts of poria cocos, 12 parts of magnolia officinalis, 10 parts of radix puerariae, 6 parts of glossy privet fruit, 8 parts of ephedra, 10 parts of almond, 10 parts of gynostemma pentaphylla, 12 parts of astragalus mongholicus, 8 parts of fructus psoraleae and 4 parts of liquorice.
6. The traditional Chinese medicine composition according to any one of claims 1-5, wherein the preparation method of the traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome is characterized in that the traditional Chinese medicine composition is prepared by weighing the raw material components according to the selected parts by weight, mixing, and extracting according to a conventional extraction method or mixing according to a conventional method.
7. Use of a Chinese medicinal composition for treating porcine reproductive and respiratory syndrome as claimed in any one of claims 1 to 5 in the preparation of a pharmaceutical formulation for treating porcine reproductive and respiratory syndrome.
8. The use according to claim 7, wherein the pharmaceutical formulation is a powder, a granule, an oral formulation, a soluble powder.
9. Use of a Chinese medicinal composition for treating porcine reproductive and respiratory syndrome as claimed in any one of claims 1 to 5 in the preparation of a feed additive for treating porcine reproductive and respiratory syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211723254.7A CN116077578A (en) | 2022-12-30 | 2022-12-30 | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211723254.7A CN116077578A (en) | 2022-12-30 | 2022-12-30 | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116077578A true CN116077578A (en) | 2023-05-09 |
Family
ID=86187815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211723254.7A Pending CN116077578A (en) | 2022-12-30 | 2022-12-30 | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116077578A (en) |
-
2022
- 2022-12-30 CN CN202211723254.7A patent/CN116077578A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114073730A (en) | Traditional Chinese medicine composition for preventing or treating air-conditioning syndrome | |
| CN105168807B (en) | The Chinese medicine composition and preparation method thereof for treating pig blue-ear disease | |
| WO2020155318A1 (en) | Traditional chinese medicine preparation for treatment of bacterial respiratory tract disease in livestock and production technique thereof | |
| CN105748734A (en) | Pure traditional Chinese medicine powder for preventing and treating pullorum disease and preparation method thereof | |
| CN103768157A (en) | Veterinary antiviral traditional Chinese medicine Ziqi effervescent granules and preparation method thereof | |
| CN110585357A (en) | Pharmaceutical composition for preventing African swine fever and injection and application thereof | |
| CN111588801B (en) | Traditional Chinese medicine dispersible granule for preventing livestock and poultry epidemic diseases and preparation method thereof | |
| CN116077578A (en) | Traditional Chinese medicine composition for treating porcine reproductive and respiratory syndrome and application thereof | |
| CN106728010A (en) | A kind of pharmaceutical composition and its preparation technology for livestock and poultry cough and asthma | |
| CN113350429A (en) | Traditional Chinese medicine composition for preventing and treating African swine fever disease and preparation method and application thereof | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN108524746B (en) | Traditional Chinese medicine composition for preventing and treating poultry cold | |
| CN111544570B (en) | Antiviral preparation added with antibacterial peptide and preparation method thereof | |
| CN115715783B (en) | Traditional Chinese medicine composition for preventing and treating white diarrhea of pigs and preparation method thereof | |
| CN114099608B (en) | Antivirus and antibacterial traditional Chinese medicine composition containing gypsum rubrum, and preparation method and application thereof | |
| CN114099607B (en) | An antiviral and antibacterial Chinese medicinal composition containing herba Moslae, and its preparation method and application | |
| CN104208213B (en) | A kind of Chinese-western medicine preparation treating chicken coccidiosis and preparation method thereof | |
| CN115990233B (en) | Traditional Chinese medicine composition for animal mycoplasma pneumonia and application thereof | |
| CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
| CN113813306B (en) | Traditional Chinese medicine composition for preventing and treating infectious rhinitis of chicken | |
| CN114099591B (en) | Antibacterial and antiviral traditional Chinese medicine composition and preparation method and application thereof | |
| CN105288346A (en) | Mouth floor cellulitis treating drug | |
| CN107510753B (en) | Traditional Chinese medicine composition for treating intractable hemoptysis and application thereof | |
| CN1957998A (en) | Animal use compound medicament with effects of removing toxic heat, removing heat from the blood to stop bleeding, and preparation method | |
| CN101085048A (en) | Traditional Chinese medicine for detoxicating for animals and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |